Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation.
Source check: Needs source check. Not independent scientific confirmation.
Finding: Four machine-learning methods were compared; the selected SVM models screened in-house compounds for dual FGFR4/EGFR inhibition. The primary abstract reports compound 1 kinase IC50 values of 86.2 and 83.9 nM, respectively. This assay result does not establish clinical efficacy.
Technology: Support-vector-machine activity models
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- SVM, random forest, gradient-boost regression tree and XGBoost models were compared after mutual-information feature selection; the best-performing SVM models predicted activity of in-house compounds.
- Test and result
- The primary abstract reports four QSAR methods and a selected dual inhibitor with IC50 86.2 nM for FGFR4 and 83.9 nM for EGFR. Assay denominator, comparator, and cell-level validation details were not present in the reviewed abstract; full ACS text was inaccessible.
- Limitation / still unknown
- Full Methods and biological-evaluation details were not reviewed. The date is unresolved: ACS header September 14 versus publication-history September 24 and PubMed Epub September 23, 2020.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1021/acs.jcim.0c00652
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 18 Nov 2026. Review scope: Indexed primary ACS/PubMed abstract and conflicting publication metadata; complete Methods/Results not reviewed..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.